Quarterly Journal of Nuclear Medicine and Molecular Imaging

Papers
(The TQCC of Quarterly Journal of Nuclear Medicine and Molecular Imaging is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Osteomyelitis in complicated bones: the role of FDG PET/CT19
Targeted alpha therapy in prostate cancer: review of available agents in clinical practice15
Role of 18F-FDG-PET/CT in assessment of pediatric Hodgkin's lymphoma14
Nuclear cardiac imaging for the diagnosis and management of heart failure: what can be learned from recent guidelines?13
Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a phantom study13
Current radioisotopes and radiopharmaceuticals for radiosynoviorthesis: basic and applied characteristics, production and availability12
Pediatric nuclear medicine: continuing the evolution11
Hybrid positron emission tomography/magnetic resonance imaging in musculoskeletal conditions: be hybrid!9
[68Ga]DOTA-TATE PET for the detection of early transplant rejection in a heterotopic allograft heart transplantation model of the rat: a pilot study9
The role of PET/CT in connective tissue disorders: systemic sclerosis, Sjögren's syndrome and systemic lupus erythematosus8
[18F]F-Choline PET/CT and 4D-CT in the evaluation of primary hyperparathyroidism: rivals or allies?8
The value of artificial intelligence in PSMA PET: a pathway to improved efficiency and results8
The role of PET/CT in large vessel vasculitis and related disorders: diagnosis, extent evaluation and assessment of therapy response7
[18F]FDG and [68Ga]Ga-PSMA dual-tracer total-body PET/CT and PET/MR in patients with prostate cancer7
Combination prostate-specific membrane antigen-targeted radiopharmaceutical therapy in metastatic prostate cancer7
Stereotactic body radiation therapy for the re-irradiation of local relapse from prostate cancer: results in terms of outcomes and toxicity6
Radiation protection aspects for alpha therapies6
Second radioiodine treatment hardly benefits TT-DTC patients with radioiodine-negative metastases on initial post-therapeutic whole-body scans6
Theragnostics before we found its name6
Evaluation of quantitative imaging parameters in head and neck squamous cell carcinoma5
Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging5
FDG PET/CT in vascular graft infection: a pictorial review5
Challenges in theragnostics5
Volumetric PET parameters are predictive for the prognosis of locally advanced cervical cancer5
Nuclear medicine and pediatric nephro-urology: a long-lasting successful partnership4
11C-methionine PET/MRI in postoperative patients after craniotomy: zero echo time and head atlas versus CT-based attenuation correction4
The role of [18F]FDG PET/CT in paraneoplastic autoimmune disorders: an umbrella review4
Perceptual omission errors in positron emission tomography and computed tomography reporting4
Technical concepts on blood pool phase SPECT (acquisition, reconstruction)4
Imaging of dopamine transporter with [18F]LBT-999: initial evaluation in healthy volunteers4
Fever of unknown origin in pediatrics: role of nuclear medicine3
F18-FET PET in pediatric brain tumors: integrative analysis of image derived parameters and clinico-pathological data3
Side effects of theragnostic agents currently employed in clinical practice3
Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors3
Towards refining the utility of dual (18F-FDG / 18F-Choline) PET/CT for the management of hepatocellular carcinoma: a tertiary center study3
Innovations in imaging modalities: a comparative review of MRI, long-axial field-of-view PET, and full-ring CZT-SPECT in detecting bone metastases3
Theragnostics applications and challenges3
Benefit of including CT urography in [68Ga]PSMA-11 PET/CT with low-dose CT: first results from a larger prostate cancer cohort analysis3
0.030957937240601